KLK3 and benign prostatic hyperplasia: When miR-142-3p is combined with serum PSA in a diagnostic model, the accuracy of distinguishing PCa from BPH improves, enhancing the efficiency of PSA-based screening and potentially reducing unnecessary biopsies.